Ptc Therapeutics (PTCT) EBIAT: 2012-2025
Historic EBIAT for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $15.9 million.
- Ptc Therapeutics' EBIAT rose 114.90% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $751.7 million, marking a year-over-year increase of 265.87%. This contributed to the annual value of -$363.3 million for FY2024, which is 42.02% up from last year.
- Per Ptc Therapeutics' latest filing, its EBIAT stood at $15.9 million for Q3 2025, which was up 124.51% from -$64.8 million recorded in Q2 2025.
- Ptc Therapeutics' EBIAT's 5-year high stood at $866.6 million during Q1 2025, with a 5-year trough of -$198.9 million in Q2 2023.
- Its 3-year average for EBIAT is -$15.7 million, with a median of -$99.2 million in 2024.
- As far as peak fluctuations go, Ptc Therapeutics' EBIAT slumped by 91.74% in 2021, and later surged by 1,046.28% in 2025.
- Ptc Therapeutics' EBIAT (Quarterly) stood at -$143.3 million in 2021, then fell by 19.28% to -$170.9 million in 2022, then increased by 8.83% to -$155.8 million in 2023, then skyrocketed by 57.71% to -$65.9 million in 2024, then surged by 114.90% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$64.8 million for Q2 2025, and $866.6 million during Q1 2025.